Preview

Variant: 1 Adult. Mild cognitive impairment not meeting criteria for dementia. Initial imaging.

Procedure	Appropriateness Category
MRI head without IV contrast	Usually Appropriate
Amyloid PET/CT brain	Usually Appropriate
CT head without IV contrast	Usually Appropriate
FDG-PET/CT brain	Usually Appropriate
MRI head without and with IV contrast	May Be Appropriate
Tau PET/CT brain	May Be Appropriate (Disagreement)
MR spectroscopy head without IV contrast	Usually Not Appropriate
MRI functional (fMRI) head without IV contrast	Usually Not Appropriate
CT head with IV contrast	Usually Not Appropriate
CT head without and with IV contrast	Usually Not Appropriate
SPECT or SPECT/CT brain perfusion	Usually Not Appropriate
SPECT or SPECT/CT brain striatal	Usually Not Appropriate

Variant: 2 Adult. Cognitive impairment with memory deficits. Suspect Alzheimer disease with typical clinical presentation. Initial imaging.

Procedure	Appropriateness Category
MRI head without IV contrast	Usually Appropriate
Amyloid PET/CT brain	Usually Appropriate
FDG-PET/CT brain	Usually Appropriate
MR spectroscopy head without IV contrast	May Be Appropriate
CT head without IV contrast	May Be Appropriate
SPECT or SPECT/CT brain perfusion	May Be Appropriate
Tau PET/CT brain	May Be Appropriate
MRI functional (fMRI) head without IV contrast	Usually Not Appropriate
MRI head without and with IV contrast	Usually Not Appropriate
CT head with IV contrast	Usually Not Appropriate
CT head without and with IV contrast	Usually Not Appropriate
SPECT or SPECT/CT brain striatal	Usually Not Appropriate

Variant: 3 Adult. Cognitive impairment with memory deficits. Suspect Alzheimer disease with atypical clinical presentation. Initial imaging.

Procedure	Appropriateness Category
MRI head without IV contrast	Usually Appropriate
Amyloid PET/CT brain	Usually Appropriate
CT head without IV contrast	Usually Appropriate
FDG-PET/CT brain	Usually Appropriate
Tau PET/CT brain	Usually Appropriate
SPECT or SPECT/CT brain perfusion	May Be Appropriate (Disagreement)
SPECT or SPECT/CT brain striatal	May Be Appropriate
MR spectroscopy head without IV contrast	Usually Not Appropriate
MRI functional (fMRI) head without IV contrast	Usually Not Appropriate
MRI head without and with IV contrast	Usually Not Appropriate
CT head with IV contrast	Usually Not Appropriate
CT head without and with IV contrast	Usually Not Appropriate

Variant: 4 Adult. Known Alzheimer disease considering therapy with anti-amyloid monoclonal antibodies. Pretreatment imaging.

Procedure	Appropriateness Category
MRI head without IV contrast	Usually Appropriate
Amyloid PET/CT brain	Usually Appropriate
Tau PET/CT brain	May Be Appropriate
MR spectroscopy head without IV contrast	Usually Not Appropriate
MRI functional (fMRI) head without IV contrast	Usually Not Appropriate
MRI head without and with IV contrast	Usually Not Appropriate
CT head with IV contrast	Usually Not Appropriate
CT head without and with IV contrast	Usually Not Appropriate
CT head without IV contrast	Usually Not Appropriate
FDG-PET/CT brain	Usually Not Appropriate
SPECT or SPECT/CT brain perfusion	Usually Not Appropriate
SPECT or SPECT/CT brain striatal	Usually Not Appropriate

Variant: 5 Adult. Known Alzheimer disease undergoing therapy with anti-amyloid monoclonal antibodies. Posttreatment imaging.

Procedure	Appropriateness Category
MRI head without IV contrast	Usually Appropriate
Amyloid PET/CT brain	May Be Appropriate (Disagreement)
MR spectroscopy head without IV contrast	Usually Not Appropriate
MRI functional (fMRI) head without IV contrast	Usually Not Appropriate
MRI head without and with IV contrast	Usually Not Appropriate
CT head with IV contrast	Usually Not Appropriate
CT head without and with IV contrast	Usually Not Appropriate
CT head without IV contrast	Usually Not Appropriate
FDG-PET/CT brain	Usually Not Appropriate
SPECT or SPECT/CT brain perfusion	Usually Not Appropriate
SPECT or SPECT/CT brain striatal	Usually Not Appropriate
Tau PET/CT brain	Usually Not Appropriate

Variant: 6 Adult. Cognitive impairment with behavioral abnormalities or progressive aphasia. Suspect frontotemporal dementia. Initial imaging.

Procedure	Appropriateness Category
MRI head without IV contrast	Usually Appropriate
CT head without IV contrast	Usually Appropriate
FDG-PET/CT brain	Usually Appropriate
Amyloid PET/CT brain	May Be Appropriate
SPECT or SPECT/CT brain perfusion	May Be Appropriate
MR spectroscopy head without IV contrast	Usually Not Appropriate
MRI functional (fMRI) head without IV contrast	Usually Not Appropriate
MRI head without and with IV contrast	Usually Not Appropriate
CT head with IV contrast	Usually Not Appropriate
CT head without and with IV contrast	Usually Not Appropriate
SPECT or SPECT/CT brain striatal	Usually Not Appropriate
Tau PET/CT brain	Usually Not Appropriate

Variant: 7 Adult. Cognitive impairment with visual hallucinations or parkinsonian symptoms. Suspect dementia with Lewy bodies. Initial imaging.

Procedure	Appropriateness Category
MRI head without IV contrast	Usually Appropriate
CT head without IV contrast	Usually Appropriate
FDG-PET/CT brain	Usually Appropriate
SPECT or SPECT/CT brain striatal	Usually Appropriate
MRI head without and with IV contrast	May Be Appropriate (Disagreement)
SPECT or SPECT/CT brain perfusion	May Be Appropriate
MR spectroscopy head without IV contrast	Usually Not Appropriate
MRI functional (fMRI) head without IV contrast	Usually Not Appropriate
Amyloid PET/CT brain	Usually Not Appropriate
CT head with IV contrast	Usually Not Appropriate
CT head without and with IV contrast	Usually Not Appropriate
Tau PET/CT brain	Usually Not Appropriate

Variant: 8 Adult. Cognitive impairment with recent stroke or stepwise decline. Suspect vascular dementia. Initial imaging.

Procedure	Appropriateness Category
MRI head without IV contrast	Usually Appropriate
MRA head without IV contrast	May Be Appropriate
MRA neck without and with IV contrast	May Be Appropriate
MRA neck without IV contrast	May Be Appropriate
CT head without IV contrast	May Be Appropriate (Disagreement)
CTA head and neck with IV contrast	May Be Appropriate
MR spectroscopy head without IV contrast	Usually Not Appropriate
MRA head without and with IV contrast	Usually Not Appropriate
MRI functional (fMRI) head without IV contrast	Usually Not Appropriate
MRI head without and with IV contrast	Usually Not Appropriate
Amyloid PET/CT brain	Usually Not Appropriate
CT head with IV contrast	Usually Not Appropriate
CT head without and with IV contrast	Usually Not Appropriate
FDG-PET/CT brain	Usually Not Appropriate
SPECT or SPECT/CT brain perfusion	Usually Not Appropriate
SPECT or SPECT/CT brain striatal	Usually Not Appropriate
Tau PET/CT brain	Usually Not Appropriate

Variant: 9 Adult. Cognitive impairment with gait disturbance or urinary incontinence. Suspect normal pressure hydrocephalus. Initial imaging.

Procedure	Appropriateness Category
MRI head without IV contrast	Usually Appropriate
CT head without IV contrast	Usually Appropriate
DTPA cisternography	May Be Appropriate
MR spectroscopy head without IV contrast	Usually Not Appropriate
MRI functional (fMRI) head without IV contrast	Usually Not Appropriate
MRI head without and with IV contrast	Usually Not Appropriate
Amyloid PET/CT brain	Usually Not Appropriate
CT head with IV contrast	Usually Not Appropriate
CT head without and with IV contrast	Usually Not Appropriate
FDG-PET/CT brain	Usually Not Appropriate
SPECT or SPECT/CT brain perfusion	Usually Not Appropriate
SPECT or SPECT/CT brain striatal	Usually Not Appropriate
Tau PET/CT brain	Usually Not Appropriate

Variant: 10 Adult. Rapidly progressive dementia. Initial imaging.

Procedure	Appropriateness Category
MRI head without and with IV contrast	Usually Appropriate
MRI head without IV contrast	Usually Appropriate
CT head without IV contrast	Usually Appropriate
MR spectroscopy head without IV contrast	Usually Not Appropriate
MRI functional (fMRI) head without IV contrast	Usually Not Appropriate
Amyloid PET/CT brain	Usually Not Appropriate
CT head with IV contrast	Usually Not Appropriate
CT head without and with IV contrast	Usually Not Appropriate
FDG-PET/CT brain	Usually Not Appropriate
SPECT or SPECT/CT brain perfusion	Usually Not Appropriate
SPECT or SPECT/CT brain striatal	Usually Not Appropriate
Tau PET/CT brain	Usually Not Appropriate

Karl A. Soderlund, MD^a; Matthew J. Austin, MD^b; Sharona Ben-Haim, MD^c; Sammy Chu, MD^d; Jana Ivanidze, MD, PhD^e; Pallavi Joshi, DO, MA^f; Aleks Kalnins, MD, MBA^g; Maura Kennedy, MD, MPH^h; Ambar Kulshreshtha, MD, PhDⁱ; Phillip H. Kuo, MD, PhD^j; Joseph C. Masdeu, MD, PhD^k; Tejas Nikumbh, MD^l; Bruno P. Soares, MD^m; Ashesh A. Thaker, MDⁿ; Lily L. Wang, MBBS, MPH^o; Sevil Yasar, MD, PhD^p; Robert Y. Shih, MD^q.

Initial imaging is defined as imaging at the beginning of the care episode for the medical condition defined by the variant. More than one procedure can be considered usually appropriate in the initial imaging evaluation when:

There are procedures that are equivalent alternatives (i.e., only one procedure will be ordered to provide the clinical information to effectively manage the patient’s care)

There are complementary procedures (i.e., more than one procedure is ordered as a set or simultaneously wherein each procedure provides unique clinical information to effectively manage the patient’s care).

The evidence table, literature search, and appendix for this topic are available at https://acsearch.acr.org/list. The appendix includes the strength of evidence assessment and the final rating round tabulations for each recommendation.

For additional information on the Appropriateness Criteria methodology and other supporting documents, please visit https://www.acr.org/Clinical-Resources/Clinical-Tools-and-Reference/Appropriateness-Criteria.

The ACR acknowledges the limitations in applying inclusive language when citing research studies that predates the use of the current understanding of language inclusive of diversity in sex, intersex, gender, and gender-diverse people. The data variables regarding sex and gender used in the cited literature will not be changed. However, this guideline will use the terminology and definitions as proposed by the National Institutes of Health.

Appropriateness Category Name	Appropriateness Rating	Appropriateness Category Definition
Usually Appropriate	7, 8, or 9	The imaging procedure or treatment is indicated in the specified clinical scenarios at a favorable risk-benefit ratio for patients.
May Be Appropriate	4, 5, or 6	The imaging procedure or treatment may be indicated in the specified clinical scenarios as an alternative to imaging procedures or treatments with a more favorable risk-benefit ratio, or the risk-benefit ratio for patients is equivocal.
May Be Appropriate (Disagreement)	5	The individual ratings are too dispersed from the panel median. The different label provides transparency regarding the panel’s recommendation. “May be appropriate” is the rating category and a rating of 5 is assigned.
Usually Not Appropriate	1, 2, or 3	The imaging procedure or treatment is unlikely to be indicated in the specified clinical scenarios, or the risk-benefit ratio for patients is likely to be unfavorable.

Potential adverse health effects associated with radiation exposure are an important factor to consider when selecting the appropriate imaging procedure. Because there is a wide range of radiation exposures associated with different diagnostic procedures, a relative radiation level (RRL) indication has been included for each imaging examination. The RRLs are based on effective dose, which is a radiation dose quantity that is used to estimate population total radiation risk associated with an imaging procedure. Patients in the pediatric age group are at inherently higher risk from exposure, because of both organ sensitivity and longer life expectancy (relevant to the long latency that appears to accompany radiation exposure). For these reasons, the RRL dose estimate ranges for pediatric examinations are lower as compared with those specified for adults (see Table below). Additional information regarding radiation dose assessment for imaging examinations can be found in the ACR Appropriateness Criteria^® Radiation Dose Assessment Introduction document.

Relative Radiation Level Designations
Relative Radiation Level*	Adult Effective Dose Estimate Range	Pediatric Effective Dose Estimate Range
O	0 mSv	0 mSv
☢	<0.1 mSv	<0.03 mSv
☢☢	0.1-1 mSv	0.03-0.3 mSv
☢☢☢	1-10 mSv	0.3-3 mSv
☢☢☢☢	10-30 mSv	3-10 mSv
☢☢☢☢☢	30-100 mSv	10-30 mSv
*RRL assignments for some of the examinations cannot be made, because the actual patient doses in these procedures vary as a function of a number of factors (e.g., region of the body exposed to ionizing radiation, the imaging guidance that is used). The RRLs for these examinations are designated as “Varies.”

1. [31638686] Arvanitakis Z, Shah RC, Bennett DA. Diagnosis and Management of Dementia: Review. [Review]. JAMA. 322(16):1589-1599, 2019 10 22.
2. [21514250] McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's dement.. 7(3):263-9, 2011 May.
3. [21764791] Villemagne VL, Ong K, Mulligan RS, et al. Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med. 2011;52(8):1210-1217.
4. [19587325] Okello A, Koivunen J, Edison P, et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology. 2009;73(10):754-760.
5. [38306055] Plassman BL, Ford CB, Smith VA, et al. Elevated Amyloid-beta PET Scan and Cognitive and Functional Decline in Mild Cognitive Impairment and Dementia of Uncertain Etiology. Journal of Alzheimer's Disease. 97(3):1161-1171, 2024.
6. [29018162] Carswell CJ, Win Z, Muckle K, et al. Clinical utility of amyloid PET imaging with (18)F-florbetapir: a retrospective study of 100 patients. Journal of Neurology, Neurosurgery & Psychiatry. 89(3):294-299, 2018 03.
7. [29889941] de Wilde A, van der Flier WM, Pelkmans W, et al. Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort: The ABIDE Project. JAMA Neurology. 75(9):1062-1070, 2018 09 01.
8. [30915522] Leuzy A, Savitcheva I, Chiotis K, et al. Clinical impact of [18F]flutemetamol PET among memory clinic patients with an unclear diagnosis. European Journal of Nuclear Medicine & Molecular Imaging. 46(6):1276-1286, 2019 Jun.
9. [31628215] Blazhenets G, Ma Y, Sorensen A, et al. Predictive Value of 18F-Florbetapir and 18F-FDG PET for Conversion from Mild Cognitive Impairment to Alzheimer Dementia. Journal of Nuclear Medicine. 61(4):597-603, 2020 04.
10. [-3198414] Society of Nuclear Medicine and Molecular Imaging. Updated Appropriate Use Criteria for Amyloid and Tau PET in Alzheimer’s Disease. Available at: https://snmmi.org/Web/Clinical-Practice/Appropriate-Use-Criteria/Articles/Updated-Appropriate-Use-Criteria-for-Amyloid-and-Tau-PET-in-Alzheimer-s-Disease.aspx.
11. [16880360] Small GW. Diagnostic issues in dementia: neuroimaging as a surrogate marker of disease. J Geriatr Psychiatry Neurol. 2006;19(3):180-185.
12. [18287270] Mosconi L, Tsui WH, Herholz K, et al. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med. 2008;49(3):390-398.
13. [18631949] Hampel H, Burger K, Teipel SJ, Bokde AL, Zetterberg H, Blennow K. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. [Review] [96 refs]. Alzheimer's dement.. 4(1):38-48, 2008 Jan.
14. [32734458] Perini G, Rodriguez-Vieitez E, Kadir A, Sala A, Savitcheva I, Nordberg A. Clinical impact of 18F-FDG-PET among memory clinic patients with uncertain diagnosis. European Journal of Nuclear Medicine & Molecular Imaging. 48(2):612-622, 2021 02.
15. [34252877] Kantarci K, Boeve BF, Przybelski SA, et al. FDG PET metabolic signatures distinguishing prodromal DLB and prodromal AD. NeuroImage Clinical. 31:102754, 2021.
16. [16443495] Soher BJ, Doraiswamy PM, Charles HC. A review of 1H MR spectroscopy findings in Alzheimer's disease. Neuroimaging Clin N Am. 2005;15(4):847-852, xi.
17. [18445744] Kantarci K.. 1H magnetic resonance spectroscopy in dementia. [Review] [72 refs][Erratum appears in Br J Radiol. 2013 Jun;86(1026):20139005]. Br J Radiol. 80 Spec No 2:S146-52, 2007 Dec.
18. [24035276] Targosz-Gajniak MG, Siuda JS, Wicher MM, et al. Magnetic resonance spectroscopy as a predictor of conversion of mild cognitive impairment to dementia. J Neurol Sci. 335(1-2):58-63, 2013 Dec 15.
19. [21807094] Hafkemeijer A, van der Grond J, Rombouts SA. Imaging the default mode network in aging and dementia. [Review]. Biochim Biophys Acta. 1822(3):431-41, 2012 Mar.
20. [31357150] Corriveau-Lecavalier N, Mellah S, Clement F, Belleville S. Evidence of parietal hyperactivation in individuals with mild cognitive impairment who progressed to dementia: A longitudinal fMRI study. NeuroImage Clinical. 24:101958, 2019.
21. [22189566] Kenny ER, Blamire AM, Firbank MJ, O'Brien JT. Functional connectivity in cortical regions in dementia with Lewy bodies and Alzheimer's disease. Brain. 135(Pt 2):569-81, 2012 Feb.
22. [19460794] Desikan RS, Cabral HJ, Hess CP, et al. Automated MRI measures identify individuals with mild cognitive impairment and Alzheimer's disease. Brain. 2009;132(Pt 8):2048-2057.
23. [20139996] Frisoni GB, Fox NC, Jack CR Jr, Scheltens P, Thompson PM. The clinical use of structural MRI in Alzheimer disease. [Review] [143 refs]. Nat Rev Neurol. 6(2):67-77, 2010 Feb.
24. [21969707] Zhang B, Zhang JG, Zhao H, et al. Evaluation of apparent diffusion coefficient mappings in amnestic mild cognitive impairment using an image analysis software brain search. Acta Radiol. 52(10):1147-54, 2011 Dec 01.
25. [23954175] Trzepacz PT, Yu P, Sun J, et al. Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia. Neurobiol Aging. 35(1):143-51, 2014 Jan.
26. [33852534] Jaleel J, Tripathi M, Baghel V, et al. F-18 ML-104 tau PET imaging in mild cognitive impairment. Nuclear Medicine Communications. 42(8):914-921, 2021 Aug 01.
27. [37690109] Cho H, Mundada NS, Apostolova LG, et al. Amyloid and tau-PET in early-onset AD: Baseline data from the Longitudinal Early-onset Alzheimer's Disease Study (LEADS). Alzheimer's & Dementia. 19 Suppl 9:S98-S114, 2023 11.
28. [31917652] Patel KP, Wymer DT, Bhatia VK, Duara R, Rajadhyaksha CD. Multimodality Imaging of Dementia: Clinical Importance and Role of Integrated Anatomic and Molecular Imaging. [Review]. Radiographics. 40(1):200-222, 2020 Jan-Feb.
29. [24849862] Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet neurol.. 13(6):614-29, 2014 Jun.
30. [29653606] Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. [Review]. Alzheimer's & Dementia. 14(4):535-562, 2018 04.
31. [35649652] Chapleau M, Iaccarino L, Soleimani-Meigooni D, Rabinovici GD. The Role of Amyloid PET in Imaging Neurodegenerative Disorders: A Review. [Review]. Journal of Nuclear Medicine. 63(Suppl 1):13S-19S, 2022 06.
32. [38934362] Jack CR, Jr., Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimers Dement 2024.
33. [21245183] Clark CM, Schneider JA, Bedell BJ, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305(3):275-283.
34. [14991808] Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306-319.
35. [32385166] Shi Z, Fu LP, Zhang N, et al. Amyloid PET in Dementia Syndromes: A Chinese Multicenter Study. Journal of Nuclear Medicine. 61(12):1814-1819, 2020 12.
36. [32808011] Iaccarino L, La Joie R, Edwards L, et al. Spatial Relationships between Molecular Pathology and Neurodegeneration in the Alzheimer's Disease Continuum. Cerebral Cortex. 31(1):1-14, 2021 01 01.
37. [20501908] Wong DF, Rosenberg PB, Zhou Y, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med. 2010;51(6):913-920.
38. [25988463] Ossenkoppele R, Jansen WJ, Rabinovici GD, et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA. 313(19):1939-49, 2015 May 19.
39. [30094462] Hellwig S, Frings L, Bormann T, Vach W, Buchert R, Meyer PT. Amyloid imaging for differential diagnosis of dementia: incremental value compared to clinical diagnosis and [18F]FDG PET. European Journal of Nuclear Medicine & Molecular Imaging. 46(2):312-323, 2019 02.
40. [37561943] Pletnikova A, Okhravi HR, Jamil N, Kirby M, Lyketsos CG, Oh ES. Utility of amyloid PET Imaging in a Memory Clinic. Alzheimer Disease & Associated Disorders. 37(4):270-273, 2023 Oct-Dec 01.
41. [29962497] Suppiah S, Ching SM, Nordin AJ, Vinjamuri S. The role of PET/CT amyloid Imaging compared with Tc99m-HMPAO SPECT imaging for diagnosing Alzheimer's disease. Medical Journal of Malaysia. 73(3):141-146, 2018 06.
42. [33219525] Lesman-Segev OH, La Joie R, Iaccarino L, et al. Diagnostic Accuracy of Amyloid versus 18 F-Fluorodeoxyglucose Positron Emission Tomography in Autopsy-Confirmed Dementia. Annals of Neurology. 89(2):389-401, 2021 02.
43. [2105589] George AE, de Leon MJ, Stylopoulos LA, et al. CT diagnostic features of Alzheimer disease: importance of the choroidal/hippocampal fissure complex. AJNR Am J Neuroradiol. 11(1):101-7, 1990 Jan-Feb.
44. [11801698] Herholz K, Schopphoff H, Schmidt M, et al. Direct comparison of spatially normalized PET and SPECT scans in Alzheimer's disease. J Nucl Med. 2002;43(1):21-26.
45. [11342678] Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56(9):1143-1153.
46. [24331205] O'Donovan J, Watson R, Colloby SJ, Blamire AM, O'Brien JT. Assessment of regional MR diffusion changes in dementia with Lewy bodies and Alzheimer's disease. Int Psychogeriatr. 26(4):627-35, 2014 Apr.
47. [29762090] Riederer I, Bohn KP, Preibisch C, et al. Alzheimer Disease and Mild Cognitive Impairment: Integrated Pulsed Arterial Spin-Labeling MRI and 18F-FDG PET. Radiology. 288(1):198-206, 2018 Jul.
48. [9527139] Talbot PR, Lloyd JJ, Snowden JS, Neary D, Testa HJ. A clinical role for 99mTc-HMPAO SPECT in the investigation of dementia?. J Neurol Neurosurg Psychiatry. 64(3):306-13, 1998 Mar.
49. [18855165] Cavallin L, Axelsson R, Wahlund LO, et al. Voxel-based correlation between coregistered single-photon emission computed tomography and dynamic susceptibility contrast magnetic resonance imaging in subjects with suspected Alzheimer disease. Acta Radiol. 2008;49(10):1154-1161.
50. [20075101] Goto H, Ishii K, Uemura T, et al. Differential diagnosis of dementia with Lewy Bodies and Alzheimer Disease using combined MR imaging and brain perfusion single-photon emission tomography. AJNR Am J Neuroradiol. 2010;31(4):720-725.
51. [31784374] Lowe VJ, Lundt ES, Albertson SM, et al. Tau-positron emission tomography correlates with neuropathology findings. Alzheimer's & Dementia. 16(3):561-571, 2020 03.
52. [32391858] Leuzy A, Smith R, Ossenkoppele R, et al. Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders. JAMA Neurology. 77(8):955-965, 2020 08 01.
53. [30326496] Ossenkoppele R, Rabinovici GD, Smith R, et al. Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA. 320(11):1151-1162, 2018 09 18.
54. [30639421] Mattsson N, Insel PS, Donohue M, et al. Predicting diagnosis and cognition with 18F-AV-1451 tau PET and structural MRI in Alzheimer's disease. Alzheimer's & Dementia. 15(4):570-580, 2019 04.
55. [35678398] Polsinelli AJ, Apostolova LG. Atypical Alzheimer Disease Variants. [Review]. CONTINUUM: Lifelong Learning in Neurology. 28(3):676-701, 2022 06 01.
56. [29107051] Ceccaldi M, Jonveaux T, Verger A, et al. Added value of 18F-florbetaben amyloid PET in the diagnostic workup of most complex patients with dementia in France: A naturalistic study. Alzheimer's & Dementia. 14(3):293-305, 2018 03.
57. [29756163] Drzezga A, Altomare D, Festari C, et al. Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimer's disease. [Review]. European Journal of Nuclear Medicine & Molecular Imaging. 45(9):1487-1496, 2018 07.
58. [31633646] Gupta V, Verma R, Ranjan R, et al. Metabolic imaging patterns in posterior cortical atrophy and Lewy body dementia. Nuclear Medicine Communications. 40(12):1275-1282, 2019 Dec.
59. [31672482] Ossenkoppele R, Lyoo CH, Sudre CH, et al. Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer's disease. Alzheimers Dement 2020;16:335-44.
60. [29105977] Phillips JS, Das SR, McMillan CT, et al. Tau PET imaging predicts cognition in atypical variants of Alzheimer's disease. Human Brain Mapping. 39(2):691-708, 2018 02.
61. [30615804] Nedelska Z, Josephs KA, Graff-Radford J, et al. 18 F-AV-1451 uptake differs between dementia with lewy bodies and posterior cortical atrophy. Movement Disorders. 34(3):344-352, 2019 03.
62. [37357276] Cummings J, Apostolova L, Rabinovici GD, et al. Lecanemab: Appropriate Use Recommendations. Jpad. 10(3):362-377, 2023.
63. [37651273] Agarwal A, Gupta V, Brahmbhatt P, et al. Amyloid-related Imaging Abnormalities in Alzheimer Disease Treated with Anti-Amyloid-beta Therapy. Radiographics. 43(9):e230009, 2023 09.
64. [37382144] Filippi M, Cecchetti G, Agosta F. MRI in the new era of antiamyloid mAbs for the treatment of Alzheimer's disease. [Review]. Current Opinion in Neurology. 36(4):239-244, 2023 08 01.
65. [37495380] Ramanan VK, Armstrong MJ, Choudhury P, et al. Antiamyloid Monoclonal Antibody Therapy for Alzheimer Disease: Emerging Issues in Neurology. Neurology 2023;101:842-52.
66. [37459141] Sims JR, Zimmer JA, Evans CD, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA 2023;330:512-27.
67. [37639461] Wang YT, Rosa-Neto P, Gauthier S. Advanced brain imaging for the diagnosis of Alzheimer disease. [Review]. Current Opinion in Neurology. 36(5):481-490, 2023 10 01.
68. [33402272] Duignan JA, Haughey A, Kinsella JA, Killeen RP. Molecular and Anatomical Imaging of Dementia With Lewy Bodies and Frontotemporal Lobar Degeneration. [Review]. Seminars in Nuclear Medicine. 51(3):264-274, 2021 05.
69. [37563165] Grossman M, Seeley WW, Boxer AL, et al. Frontotemporal lobar degeneration. Nat Rev Dis Primers 2023;9:40.
70. [25171901] Diehl-Schmid J, Onur OA, Kuhn J, Gruppe T, Drzezga A. Imaging frontotemporal lobar degeneration. [Review]. Curr Neurol Neurosci Rep. 14(10):489, 2014 Oct.
71. [12821731] Rombouts SA, van Swieten JC, Pijnenburg YA, Goekoop R, Barkhof F, Scheltens P. Loss of frontal fMRI activation in early frontotemporal dementia compared to early AD. Neurology. 60(12):1904-8, 2003 Jun 24.
72. [25002573] Dopper EG, Rombouts SA, Jiskoot LC, et al. Structural and functional brain connectivity in presymptomatic familial frontotemporal dementia. Neurology. 83(2):e19-26, 2014 Jul 08.
73. [38012398] Perez-Millan A, Borrego-Ecija S, Falgas N, et al. Cortical thickness modeling and variability in Alzheimer's disease and frontotemporal dementia. J Neurol 2024;271:1428-38.
74. [37500561] Assogna M, Premi E, Gazzina S, et al. Association of Choroid Plexus Volume With Serum Biomarkers, Clinical Features, and Disease Severity in Patients With Frontotemporal Lobar Degeneration Spectrum. Neurology. 101(12):e1218-e1230, 2023 09 19.
75. [22976075] Zhang Y, Tartaglia MC, Schuff N, et al. MRI signatures of brain macrostructural atrophy and microstructural degradation in frontotemporal lobar degeneration subtypes. J Alzheimers Dis. 33(2):431-44, 2013.
76. [30704514] Tsai RM, Bejanin A, Lesman-Segev O, et al. 18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes. Alzheimer's Research & Therapy. 11(1):13, 2019 01 31.
77. [30594046] Cho H, Kim HJ, Choi JY, et al. 18F-flortaucipir uptake patterns in clinical subtypes of primary progressive aphasia. Neurobiology of Aging. 75:187-197, 2019 03.
78. [33824991] Pascual B, Funk Q, Zanotti-Fregonara P, et al. Neuroinflammation is highest in areas of disease progression in semantic dementia. Brain 2021;144:1565-75.
79. [33926896] Oldan JD, Jewells VL, Pieper B, Wong TZ. Complete Evaluation of Dementia: PET and MRI Correlation and Diagnosis for the Neuroradiologist. [Review]. Ajnr: American Journal of Neuroradiology. 42(6):998-1007, 2021 06.
80. [23831180] Donaghy P, Thomas AJ, O'Brien JT. Amyloid PET Imaging in Lewy body disorders. [Review]. Am J Geriatr Psychiatry. 23(1):23-37, 2015 Jan.
81. [37421880] Feng LR, Vogel A, Mellergaard C, et al. Clinical validation of the cingulate island sign visual rating scale in dementia with Lewy bodies. Journal of the Neurological Sciences. 451:120719, 2023 08 15.
82. [24468473] Graff-Radford J, Boeve BF, Murray ME, et al. Regional proton magnetic resonance spectroscopy patterns in dementia with Lewy bodies. Neurobiol Aging. 35(6):1483-90, 2014 Jun.
83. [26572170] Watson R, Colloby SJ, Blamire AM, O'Brien JT. Subcortical volume changes in dementia with Lewy bodies and Alzheimer's disease. A comparison with healthy aging. Int Psychogeriatr. 28(4):529-36, 2016 Apr.
84. [36123123] Constant AB, Basavaraju R, France J, Honig LS, Marder KS, Provenzano FA. Longitudinal Patterns of Cortical Atrophy on MRI in Patients With Alzheimer Disease With and Without Lewy Body Pathology. Neurology. 99(17):e1843-e1852, 2022 Oct 24.
85. [18692749] Fayed N, Davila J, Oliveros A, Castillo J, Medrano JJ. Utility of different MR modalities in mild cognitive impairment and its use as a predictor of conversion to probable dementia. Acad Radiol. 2008;15(9):1089-1098.
86. [19142710] Shimizu S, Hanyu H, Hirao K, Sato T, Iwamoto T, Koizumi K. Value of analyzing deep gray matter and occipital lobe perfusion to differentiate dementia with Lewy bodies from Alzheimer's disease. Ann Nucl Med. 2008;22(10):911-916.
87. [38315966] Rahayel S, Postuma R, Baril AA, et al. 99mTc-HMPAO SPECT Perfusion Signatures Associated With Clinical Progression in Patients With Isolated REM Sleep Behavior Disorder. Neurology. 102(4):e208015, 2024 Feb.
88. [36920494] Jreige M, Kurian GK, Perriraz J, et al. The diagnostic performance of functional dopaminergic scintigraphic imaging in the diagnosis of dementia with Lewy bodies: an updated systematic review. [Review]. European Journal of Nuclear Medicine & Molecular Imaging. 50(7):1988-2035, 2023 06.
89. [32198310] Maltais DD, Jordan LG, Min HK, et al. Confirmation of 123I-FP-CIT SPECT Quantification Methods in Dementia with Lewy Bodies and Other Neurodegenerative Disorders. Journal of Nuclear Medicine. 61(11):1628-1635, 2020 11.
90. [27654968] Gomperts SN, Locascio JJ, Makaretz SJ, et al. Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases. JAMA Neurol 2016;73:1334-41.
91. [33631469] Mak E, Nicastro N, Malpetti M, et al. Imaging tau burden in dementia with Lewy bodies using [(18)F]-AV1451 positron emission tomography. Neurobiol Aging 2021;101:172-80.
92. [35678401] Chang Wong E, Chang Chui H. Vascular Cognitive Impairment and Dementia. [Review]. CONTINUUM: Lifelong Learning in Neurology. 28(3):750-780, 2022 06 01.
93. [37271126] Yang X, Chen C, Wang A, Li C, Cheng G. Imaging, Genetic, and Pathological Features of Vascular Dementia. [Review]. European Neurology. 86(4):277-284, 2023.
94. [15729521] Singhal S, Markus HS. Cerebrovascular reactivity and dynamic autoregulation in nondemented patients with CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy). J Neurol 2005;252:163-7.
95. [8094895] Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 43(2):250-60, 1993 Feb.
96. [31929166] Frantellizzi V, Pani A, Ricci M, Locuratolo N, Fattapposta F, De Vincentis G. Neuroimaging in Vascular Cognitive Impairment and Dementia: A Systematic Review. Journal of Alzheimer's Disease. 73(4):1279-1294, 2020.
97. [22135130] Murray AD. Imaging Approaches for Dementia. AJNR Am J Neuroradiol. 2011;33(10):1836-1844.
98. [29932266] Nobili F, Arbizu J, Bouwman F, et al. European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain 18 F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus. European Journal of Neurology. 25(10):1201-1217, 2018 10.
99. [1513253] Sappey-Marinier D, Calabrese G, Hetherington HP, et al. Proton magnetic resonance spectroscopy of human brain: applications to normal white matter, chronic infarction, and MRI white matter signal hyperintensities. Magn Reson Med. 26(2):313-27, 1992 Aug.
100. [18436880] Nitkunan A, Barrick TR, Charlton RA, Clark CA, Markus HS. Multimodal MRI in cerebral small vessel disease: its relationship with cognition and sensitivity to change over time. Stroke. 39(7):1999-2005, 2008 Jul.
101. [24557016] Brundel M, Kwa VI, Bouvy WH, et al. Cerebral microbleeds are not associated with long-term cognitive outcome in patients with transient ischemic attack or minor stroke. Cerebrovasc Dis. 37(3):195-202, 2014.
102. [35614521] Lee H, Wiggermann V, Rauscher A, et al. Brain Imaging Abnormalities in Mixed Alzheimer's and Subcortical Vascular Dementia. Canadian Journal of Neurological Sciences. 50(4):515-528, 2023 07.
103. [26644048] Halperin JJ, Kurlan R, Schwalb JM, Cusimano MD, Gronseth G, Gloss D. Practice guideline: Idiopathic normal pressure hydrocephalus: Response to shunting and predictors of response: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. [Review][Erratum appears in Neurology. 2016 Feb 23;86(8):793; PMID: 26903492]. Neurology. 85(23):2063-71, 2015 Dec 08.
104. [37898265] Giorgio C, Marcello L, Enricomaria M, et al. Magnetic Resonance Imaging Diagnosis in Normal Pressure Hydrocephalus. [Review]. World Neurosurgery. 181:171-177, 2024 Jan.
105. [32906629] Mattoli MV, Treglia G, Calcagni ML, Mangiola A, Anile C, Trevisi G. Usefulness of Brain Positron Emission Tomography with Different Tracers in the Evaluation of Patients with Idiopathic Normal Pressure Hydrocephalous. International Journal of Molecular Sciences. 21(18), 2020 Sep 07.
106. [33395973] Cogswell PM, Graff-Radford J, Wurtz LI, et al. CSF dynamics disorders: Association of brain MRI and nuclear medicine cisternogram findings. NeuroImage Clinical. 28:102481, 2020.
107. [29876274] Townley RA, Botha H, Graff-Radford J, et al. 18F-FDG PET-CT pattern in idiopathic normal pressure hydrocephalus. NeuroImage Clinical. 18:897-902, 2018.
108. [20647518] Algin O, Hakyemez B, Parlak M. Proton MR spectroscopy and white matter hyperintensities in idiopathic normal pressure hydrocephalus and other dementias. Br J Radiol. 83(993):747-52, 2010 Sep.
109. [27042906] Geschwind MD. Rapidly Progressive Dementia. Continuum (Minneap Minn) 2016;22:510-37.
110. [23436051] Degnan AJ, Levy LM. Neuroimaging of rapidly progressive dementias, part 1: neurodegenerative etiologies. [Review]. Ajnr: American Journal of Neuroradiology. 35(3):418-23, 2014 Mar.
111. [23413251] Degnan AJ, Levy LM. Neuroimaging of rapidly progressive dementias, part 2: prion, inflammatory, neoplastic, and other etiologies. [Review]. Ajnr: American Journal of Neuroradiology. 35(3):424-31, 2014 Mar.
112. [37698615] Manara R, Fragiacomo F, Ladogana A, et al. MRI abnormalities in Creutzfeldt-Jakob disease and other rapidly progressive dementia. Journal of Neurology. 271(1):300-309, 2024 Jan.
113. [36304377] Khan A, Elkady A, Rahametallah M, Bakheet MF. Dural Arteriovenous Fistula Presenting as a Rapidly Progressive Thalamic Dementia: A Case Report. Cureus 2022;14:e29392.
114. [35286054] National Academies of Sciences, Engineering, and Medicine; Division of Behavioral and Social Sciences and Education; Committee on National Statistics; Committee on Measuring Sex, Gender Identity, and Sexual Orientation. Measuring Sex, Gender Identity, and Sexual Orientation. In: Becker T, Chin M, Bates N, eds. Measuring Sex, Gender Identity, and Sexual Orientation. Washington (DC): National Academies Press (US) Copyright 2022 by the National Academy of Sciences. All rights reserved.; 2022.
115. [-3128692] American College of Radiology. ACR Appropriateness Criteria® Radiation Dose Assessment Introduction. Available at: https://edge.sitecorecloud.io/americancoldf5f-acrorgf92a-productioncb02-3650/media/ACR/Files/Clinical/Appropriateness-Criteria/ACR-Appropriateness-Criteria-Radiation-Dose-Assessment-Introduction.pdf.

The ACR Committee on Appropriateness Criteria and its expert panels have developed criteria for determining appropriate imaging examinations for diagnosis and treatment of specified medical condition(s). These criteria are intended to guide radiologists, radiation oncologists and referring physicians in making decisions regarding radiologic imaging and treatment. Generally, the complexity and severity of a patient’s clinical condition should dictate the selection of appropriate imaging procedures or treatments. Only those examinations generally used for evaluation of the patient’s condition are ranked. Other imaging studies necessary to evaluate other co-existent diseases or other medical consequences of this condition are not considered in this document. The availability of equipment or personnel may influence the selection of appropriate imaging procedures or treatments. Imaging techniques classified as investigational by the FDA have not been considered in developing these criteria; however, study of new equipment and applications should be encouraged. The ultimate decision regarding the appropriateness of any specific radiologic examination or treatment must be made by the referring physician and radiologist in light of all the circumstances presented in an individual examination